SuspendedNot Applicable

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Stopped: Accrual Limit

United States5,200 participantsStarted 2017-04-18

Plain-language summary

This randomized clinical trial studies how well online genetics educational video with or without pre- and/or post-telephone genetics counseling works in assessing cancer-risk distress in patients with triple negative breast cancer. Online genetic education and telephone genetic counseling may help the doctors learn the stress a person feels about their risk of cancer.

Who can participate

Age range

30 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 30 or older. Note: Participants must meet each of Criteria 1-4. * Have access to a healthcare provider and be willing to share genetic results with that provider * Have at least one ovary * Have a valid United States mailing address for receipt of saliva kit * Participants must meet any one of the following 6 criteria: * Diagnosed with breast cancer at age 45 or younger * Diagnosed with triple negative (negative for estrogen receptor, progesterone receptor and not human epidermal growth factor receptor 2 \[Her2\] amplified) breast cancer at 60 or younger * Have one blood relative with a mutation in BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, BARD1, MSH2, MSH6, MLH1, or PMS2 * Have one relative with ovarian cancer * Have at least 2 relatives with breast cancer on the same side of the family, one of which is =\< 50 years of age * Have one male relative with breast cancer Exclusion Criteria: * Personal history of ovarian cancer * Unable to read, speak, and understand English * Unable to provide informed consent * Unwilling to complete baseline and follow-up questionnaires * Unable to access the internet * Previous genetic testing or counseling regarding cancer risk * Previous bone marrow transplant * Previous blood transfusion (7 days prior to genetic testing) * Active hematologic malignancy (cancer that begins in blood-forming tissue, such as leukemia or lymphoma)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Mean cancer stress scores

Timeframe: Up to 4 years

Trial details

NCT IDNCT02993068

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04-18

View on ClinicalTrials.gov More BARD1 Gene Mutation trials